You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: December 9, 2023

CERIANNA Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Cerianna, and what generic alternatives are available?

Cerianna is a drug marketed by Ge Healthcare and is included in one NDA.

The generic ingredient in CERIANNA is fluoroestradiol f-18. One supplier is listed for this compound. Additional details are available on the fluoroestradiol f-18 profile page.

Summary for CERIANNA
US Patents:0
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 5
Patent Applications: 19
What excipients (inactive ingredients) are in CERIANNA?CERIANNA excipients list
DailyMed Link:CERIANNA at DailyMed
Drug patent expirations by year for CERIANNA
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for CERIANNA
Generic Entry Date for CERIANNA*:
Constraining patent/regulatory exclusivity:

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for CERIANNA

US Patents and Regulatory Information for CERIANNA

CERIANNA is protected by zero US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of CERIANNA is ⤷  Try a Trial.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

FDA Regulatory Exclusivity protecting CERIANNA

Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare CERIANNA fluoroestradiol f-18 SOLUTION;INTRAVENOUS 212155-001 May 20, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.